Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 585-591

  Degirmenci, M ^a   Karaca, B ^a   Gorumlu, G ^a   Durusoy, R ^a   Demir Piskin, G ^b   Bozkurt, M T ^b   Cirak, Y ^a   Tunali, D ^a   Karabulut, B ^a   Sanli, U A ^a   Uslu, R ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

Author keywords

Bevacizumab; Capecitabine; Irinotecan; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; VASCULOTROPIN;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SEX DIFFERENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956938872     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9253-5     Document Type: Article

References (17)

1. A Cercek LB Saltz 2008 First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents Clin Colorectal Cancer 7 Suppl 2 47 51 10.3816/CCC.2008.s.007
2. A De Gramont, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2938 2947 10944126
3. JL Chase 2008 Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer Pharmacotherapy 28 23 30 10.1592/phco.28.11-supp.23S
4. N Uemura Y Yamada 2006 FOLFIRI regimen for metastatic or recurrent colorectal cancer Gan To Kagaku Ryoho 33 7 904 906 1:CAS:528: DC%2BD28XotFaqtb8%3D 16835477
5. JP Delord, et al. 2002 Dose escalation, pharmacokinetic study of capecitabine (Xeloda), irinotecan (CPATİENT-11) in gastrointestinal tumors Proc Am Soc Clin Oncol 21 A397
6. DJ Kerr, et al. 2002 A phase I/II study of CPATİENT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (mCRC) Proc Am Soc Clin Oncol 21 A643
7. C Twelves S Gollins R Grieve L Samuel 2006 A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer Ann Oncol 17 239 245 10.1093/annonc/mdj023 1:STN:280:DC%2BD28%2FjvVGktg%3D%3D 16344278 (Pubitemid 43160112)
8. P Therasse, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
9. J Tol, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 563 572 10.1056/NEJMoa0808268 1:CAS:528:DC%2BD1MXhsFyitrw%3D 19196673
10. H Hurwitz, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
11. F Kabbinavar, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 1 60 65 10.1200/JCO.2003.10. 066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
12. FF Kabbinavar, et al. 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: result of a randomized phase II trial J Clin Oncol 23 16 3697 3705 10.1200/JCO.2005.05.112 1:CAS:528:DC%2BD2MXlslWntr0%3D 15738537
13. Cartwright TH, Encarnacion C, Vukelja S, et al. A phase II open-label study of capecitabine in combination with irinotecan as first line treatment for mCRC. Gastrointestinal cancers symposium: current status and future direction for prevention and management, San Francisco, CA, Abstract 271, 2004.
14. YZ Patt E Lin J Liebman, et al. 2004 Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (mCRC) Proc Am Soc Clin Oncol 23 A228
15. E Bajetta, et al. 2004 Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in mCRC Cancer 100 2 279 287 10.1002/cncr.11910 1:CAS:528: DC%2BD2cXhtVOhu7Y%3D 14716761 (Pubitemid 38063635)
16. A Ardavanis, et al. 2008 Bevcizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen Anticancer Res 28 3087 3092 1:CAS:528: DC%2BD1cXhsVaitrnF 19031962
17. M Moehler, et al. 2009 Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients World J Gastroenterol 15 4 449 456 10.3748/wjg.15.449 1:CAS:528:DC%2BD1MXisVSmt7s%3D 19152449